# Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

> **NCT02586025** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 329 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** FEC Chemotherapy
- **PROCEDURE:** Surgery
- **DRUG:** Docetaxel
- **DRUG:** Pertuzumab
- **DRUG:** Placebo
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02586025
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-14
- **Primary completion:** 2017-10-23
- **Final completion:** 2022-03-14
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586025, "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02586025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*